Stock-Based Compensation (Tables)
|
3 Months Ended |
Mar. 31, 2026 |
|---|
| Share-Based Payment Arrangement [Abstract] |
|
| Schedule of Stock Option Activity |
The following table summarizes the Company’s stock option activity since December 31, 2025 (in thousands, except for share and per share data): | | | | | | | | | | | | | | | | | | | | | | | | | Number of
Shares | | Weighted
Average
Exercise Price | | Weighted
Average
Remaining
Contractual Term (in years) | | Aggregate
Intrinsic Value | | | | | | | | | Outstanding as of December 31, 2025 | 8,184,004 | | $ | 1.25 | | | | | | | | | | | | | | | Exercised | (482,435) | | | 0.67 | | | | | | | | | | | | | | | | | | | | | | Outstanding as of March 31, 2026 | 7,701,569 | | $ | 1.29 | | | 4.2 | | $ | 36,684 | | | | | | | | | | Vested and expected to vest as of March 31, 2026 | 7,701,569 | | $ | 1.29 | | | 4.2 | | $ | 36,684 | | Options exercisable as of March 31, 2026 | 7,070,412 | | $ | 1.09 | | | 3.9 | | $ | 35,037 | |
|
| Schedule of Restricted Stock Unit Activity |
The following table summarizes the Company's restricted stock units activity since December 31, 2025: | | | | | | | | | | | | | Number of
Shares | | Grant Date Fair
Value | | | | | Nonvested as of December 31, 2025 | 10,660,163 | | | $ | 3.85 | | | Granted | 3,948,290 | | | 5.44 | | | Vested | (3,576,310) | | | 3.40 | | | Forfeited | (184,530) | | | 4.71 | | Nonvested as of March 31, 2026 | 10,847,613 | | | $ | 4.57 | |
|
| Schedule of Fair Value Weighted-Average Assumptions |
The fair value of the awards was estimated based on a Monte Carlo simulation model, on a weighted average basis: | | | | | | | | | | | | | Three Months Ended March 31, | | 2026 | | 2025 | | Risk-free interest rate | 3.4% | | 4.0% | | Expected term (in years) | 3.0 | | 3.0 | | Expected volatility | 83.0% | | 91.7% | | Expected dividend yield | 0.0% | | 0.0% |
|
| Schedule Of Market Based Stock Activity |
The following table summarizes the Company's market-condition stock-based awards activity since December 31, 2025: | | | | | | | | | | | | | Number of
Shares | | Grant Date Fair
Value | | | | | Nonvested as of December 31, 2025 | 1,670,143 | | | $ | 4.93 | | | Granted | 1,130,835 | | | 9.47 | | | | | | | | | | Nonvested as of March 31, 2026 | 2,800,978 | | | $ | 6.77 | |
|
| Schedule of Allocation of Share Based Compensation Expense |
Stock-based compensation expense was classified in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): | | | | | | | | | | | | | | | | | Three Months Ended March 31, | | | | 2026 | | 2025 | | | | | | Cost of revenue | $ | 315 | | $ | 219 | | | | | | Research and development | 1,280 | | 1,115 | | | | | | Sales and marketing | 1,566 | | 1,048 | | | | | | General and administrative | 2,426 | | 1,972 | | | | | | Restructuring costs | $ | — | | $ | 525 | | | | | | Total stock-based compensation expense | $ | 5,587 | | $ | 4,879 | | | | |
|